Company news
Genscript Biotech Corporation news in 2026
Genscript Biotech Corporation's news releases, calls and decks from 2026, newest first.
Voluntary announcement: unusual price movement
November 3, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 3, 2026
Passing away of company secretary and process agent
November 2, 2026
Voluntary announcement: legend announces preliminary sales for CARVYKTI for the quarter ended 30 September 2026
October 13, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 6, 2026
Change in board lot size
September 21, 2026
Announcement pursuant to rule 13.10 of the listing rules
September 17, 2026
List of directors and their role and function
September 16, 2026
Passing away of an independent non-executive director and change in composition of board committees
September 16, 2026
Interim report 2026
September 16, 2026
Next Day Disclosure Return
September 15, 2026
Completion of placing of new shares under the general mandate
September 15, 2026
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
August 18, 2026
GenScript Sets New Benchmark for Responsible Biotech Leadership with 2025 ESG Report
April 14, 2026
GenScript and Mimulus Partner to Industrialize DNA-Based Data Storage for the AI Era
April 9, 2026
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
March 16, 2026
GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco
January 29, 2026
GenScript is Scripting Possibilities in AI-Driven Drug Discovery as Wet-Lab Partner for Latent-X2 Innovation
January 28, 2026
'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week
January 6, 2026